In breast cancers with amplified ERBB2, ErbB3 augments ErbB2 signaling through strong coupling to survival pathways that complement the signals emanating from ErbB2, thus allowing the cancer cells to escape from inhibition therapy [15]. This evidence concerns the gene ERBB2 and breast cancer.